Among 200 patients with primary myelofibrosis, karyotype at diagnosis was abnormal in 83 (42%). In order to assess their individual prognostic impact, specific cytogenetic abnormalities with ≥ 5 informative cases were identified and the rest grouped separately as "other abnormalities". Median survival in patients with sole +9 (n=6), sole 20q-(n=21), sole 13q-(n=8), normal karyotype (n=117), "other abnormalities" (n=28), complex karyotype (n=13), and sole +8 (n=7) were "not reached ", 112, 105, 80, 46, 34 and 28 months, respectively (p=0.01). Accordingly, four cytogenetic risk groups were considered: i) favorable (sole +9, 20q-or 13q-), ii) normal, iii) unfavorable (complex karyotype or sole +8), and iv) "other abnormalities". Multivariable analysis confirmed the International Prognostic Scoring System (IPSS)-independent prognostic value of both 4-way and 2-way (i.e. favorable/normal vs. unfavorable/other abnormalities; IPSSadjusted HR 0.37, 95% CI 0.24-0.58) cytogenetic risk categorization (p<0.01). The ability to prognostically dissect a specific IPSS category has major therapeutic implications.
Introduction
Among myeloid malignancies, cytogenetic information has established prognostic value in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and is incorporated into formal prognostic systems.
1,2 Similarly, the prognostic value of cytogenetic findings in primary myelofibrosis (PMF) has long been suggested [3] [4] [5] and recently reiterated in three separate studies. [6] [7] [8] The latter were all in agreement regarding the favorable prognostic impact of sole abnormalities of 20q-and 13q-. 4, 9 In addition, one of the three studies 7 identified +9 (plus/minus one other abnormality) as another favorable prognostic marker in PMF but the number of informative patients (n=3 out of 131 evaluated at diagnosis) was too small to be certain about the particular observation.
Similarly small sample sizes make it difficult to fully acknowledge observations from previous studies regarding the detrimental effect of -7/7q-, 7,10,11 -5/5q-, 7 -17(or other abnormalities of chromosome 17), 7 12p-, 4 +8, 4 +13, 12 and complex karyotype. 7 In the current study, we expanded our cohort of PMF patients with cytogenetic information at or near the time of diagnosis (n=200), in order to i) validate some of the above-mentioned observations and ii) examine the prognostic interaction between cytogenetic risk categorization and the International Prognostic Scoring System (IPSS) for PMF. 
Methods
After approval by the Mayo Clinic Institutional Review Board, clinical and laboratory data were collected from adult patients (≥18 years) with PMF, in whom cytogenetic information at or within 6 months of diagnosis (and prior to initiation of specific therapy) was available. 
Results and discussion
Two hundred patients with PMF met the above-stipulated criteria for study inclusion; an additional 22 patients were excluded because of inadequate number of metaphases. Clinical and laboratory features of the study population are outlined in supplemental table 1. The IPSS risk distributions were low in 66 (33%) patients, intermediate (int)-1 in 64 (32%), int-2 in 44 (22%) and high in 26 (13%). JAK2V617F mutation analysis was performed in 167 patients and 104 (62%) were mutation-positive.
Cytogenetic findings were normal in 117 (58%) patients. Among the 83 (42%) patients with abnormal karyotype, twenty-one displayed sole 20q-, eight sole 13q-, seven sole +8 and six sole +9. Thirteen patients had complex karyotype (≥ 3 cytogenetic abnormalities) and 28 had cytogenetic abnormalities that individually occurred in less than 5 patients and therefore grouped in the "other abnormalities" category.
At the time of this report, median follow-up was 41 months and 99 (50%) deaths were recorded. Causes of death were documented in 52 cases and their distribution among the different cytogenetic groups is outlined in supplemental Figure 1A ). Consideration of two (i.e. favorable/normal vs. unfavorable/other abnormalities) instead of four cytogenetic groups also resulted in significant survival differences (82 vs. 42 months; p=0.0007; Figure 1B ).
Multivariable analysis confirmed the IPSS-independent prognostic value of both 2-way and 4-way cytogenetic risk categorization (p<0.01 in both instances); the corresponding IPSS-adjusted hazard ratios (HR) and 95% confidence intervals (CI) are provided in supplemental table 2. Additional analysis within specific IPSS categories disclosed that prognostic distinction was most apparent in the IPSS int-1 risk category (Figures 1C and 1D ; supplemental Table 3 ). JAK2V617F mutational status did not affect survival either in the entire cohort of study patients (p=0.27) or when analysis was restricted to IPSS int-1 risk group (p=0.63).
The results of the current study have major therapeutic implications. Allo-HCT is currently the only treatment approach in PMF that is potentially curative. 18 However, most patients and physicians alike show limited enthusiasm for such therapy because of the associated high treatment-related mortality and morbidity. 19 making for the individual patient is highly desired and the results of the current study support the value of cytogenetic information in that regard. Accordingly, we recommend application of IPSS risk stratification first followed by second-level prognostication using cytogenetic data.
Finally, the current study, by virtue of its larger sample size of informative cases evaluated at the time of diagnosis, validates the recent observations by Tam et al. regarding the respective favorable and unfavorable prognostic impact of sole +9 and complex karyotype. 7 Similarly adequate number of patients were included to also confirm our own previous observations regarding the adverse prognostic impact of sole +8. 4 On the other hand, the number of informative patients with -7/7q-was not large enough to help clarify the discrepancy between recent studies regarding its prognostic value. 7, 8, 10 The same can be said regarding abnormalities of chromosomes 5, 17 or non-complex combinations of good-risk and high-risk abnormalities. Larger number of study patients is needed to resolve these issues and determine the prospect of including cytogenetic information during future revisions of the IPSS. 13 For 
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